The Kirby-Bauer disk diffusion assay can distinguish between bacteriostatic and bactericidal agents

1. Van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet (2006) 368(9547):1554–6. 10.1016/S0140-6736(06)69575-5 [PubMed] [CrossRef] [Google Scholar]

2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis (2013) 13(12):1057–98. 10.1016/S1473-3099(13)70318-9 [PubMed] [CrossRef] [Google Scholar]

3. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature (2016) 529(7586):336–43. 10.1038/nature17042 [PubMed] [CrossRef] [Google Scholar]

4. Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med (2016) 375(11):1081–9. 10.1056/NEJMsr1512438 [PubMed] [CrossRef] [Google Scholar]

5. WHO. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Geneva: World Health Organization; (2017). [Google Scholar]

6. Davies SC, Fowler T, Watson J, Livermore DM, Walker D. Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance. Lancet (2013) 381(9878):1606–9. 10.1016/S0140-6736(13)60604-2 [PubMed] [CrossRef] [Google Scholar]

7. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis (2017) 17(2):e56–63. 10.1016/S1473-3099(16)30386-3 [PubMed] [CrossRef] [Google Scholar]

8. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, et al. Requirements for high impact diagnostics in the developing world. Nature (2006) 444(Suppl 1):73–9. 10.1038/nature05448 [PubMed] [CrossRef] [Google Scholar]

9. Kanthor R. Diagnostics: detection drives defence. Nature (2014) 509(7498):S14–5. 10.1038/509S14a [PubMed] [CrossRef] [Google Scholar]

10. CLSI. Performance Standards for Antimicrobial Performance Standards for Antimicrobial Susceptibility Testing-26th Edition: CLSI Supplement M100S. Wayne, PA: NCCLS; (2016). [Google Scholar]

11. CLSI. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition M24-A2. Wayne, PA: NCCLS; (2011). [Google Scholar]

12. Ceyssens PJ, Soetaert K, Timke M, Van den Bossche A, Sparbier K, De Cremer K, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for combined species identification and drug sensitivity testing in mycobacteria. J Clin Microbiol (2017) 55(2):624–34. 10.1128/JCM.02089-16 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Machen A, Drake T, Wang YF. Same day identification and full panel antimicrobial susceptibility testing of bacteria from positive blood culture bottles made possible by a combined lysis-filtration method with MALDI-TOF VITEK mass spectrometry and the VITEK2 system. PLoS One (2014) 9(2):e87870. 10.1371/journal.pone.0087870 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Idelevich EA, Sparbier K, Kostrzewa M, Becker K. Rapid detection of antibiotic resistance by MALDI-TOF mass spectrometry using a novel direct-on-target microdroplet growth assay. Clin Microbiol Infect (2017). 10.1016/j.cmi.2017.10.016 [PubMed] [CrossRef] [Google Scholar]

15. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis (2016) 16(10):1185–92. 10.1016/S1473-3099(16)30190-6 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Aragon LM, Garrigo M, Moreno C, Espanol M, Coll P. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. J Antimicrob Chemother (2007) 60(3):655–7. 10.1093/jac/dkm252 [PubMed] [CrossRef] [Google Scholar]

17. Hewlett D, Jr, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA (1995) 273(12):916–7. 10.1001/jama.273.12.916 [PubMed] [CrossRef] [Google Scholar]

18. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis (2003) 7(1):6–21. [PubMed] [Google Scholar]

19. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2010) 48(1):300–1. 10.1128/JCM.01775-09 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2012) 50(2):428–34. 10.1128/JCM.05435-11 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Feng J, Wang T, Zhang S, Shi W, Zhang Y. An optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi. PLoS One (2014) 9(11):e111809. 10.1371/journal.pone.0111809 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Barbesti S, Citterio S, Labra M, Baroni MD, Neri MG, Sgorbati S. Two and three-color fluorescence flow cytometric analysis of immunoidentified viable bacteria. Cytometry (2000) 40(3):214–8. 10.1002/1097-0320(20000701)40:3<214::AID-CYTO6>3.0.CO;2-M [PubMed] [CrossRef] [Google Scholar]

23. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2009) 13(11):1320–30. [PubMed] [Google Scholar]

24. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect (2013) 2(6):e34. 10.1038/emi.2013.38 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg Microbes Infect (2014) 3(7):e49. 10.1038/emi.2014.53 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Zhang Y, Chiu Chang K, Leung CC, Wai Yew W, Gicquel B, Fallows D, et al. “Z(S)-MDR-TB’ versus ‘Z(R)-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect (2012) 1(7):e5. 10.1038/emi.2012.18 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr (2014) 2(4). 10.1128/microbiolspec.MGM2-0023-2013 [PubMed] [CrossRef] [Google Scholar]

28. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol (1999) 181(7):2044–9. [PMC free article] [PubMed] [Google Scholar]

29. Wade MM, Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother (2006) 58(5):936–41. 10.1093/jac/dkl358 [PubMed] [CrossRef] [Google Scholar]

30. Fredricks BA, DeCoster DJ, Kim Y, Sparks N, Callister SM, Schell RF. Rapid pyrazinamide susceptibility testing of Mycobacterium tuberculosis by flow cytometry. J Microbiol Methods (2006) 67(2):266–72. 10.1016/j.mimet.2006.03.020 [PubMed] [CrossRef] [Google Scholar]

31. Mole R, Trollip A, Abrahams C, Bosman M, Albert H. Improved contamination control for a rapid phage-based rifampicin resistance test for Mycobacterium tuberculosis. J Med Microbiol (2007) 56(Pt 10):1334–9. 10.1099/jmm.0.46936-0 [PubMed] [CrossRef] [Google Scholar]

32. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 66(3):219–25. 10.1016/0041-3879(85)90040-6 [PubMed] [CrossRef] [Google Scholar]

Page 2

PMC full text:

Copyright/LicenseRequest permission to reuse

Copyright © 2018 Feng, Yee, Zhang, Tian, Shi, Zhang and Zhang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

SYBR Green I/propidium iodide (PI) stain can distinguish between R (resistant) and S (sensitive) strains of Gram-negative pathogens against various antibiotics in 30 min. Treatment with (A) ampicillin (100 µg/ml), (B) trimethoprim (50 µg/ml), and (C) streptomycin (50 µg/ml) was added to overnight cultures of Escherichia coli strains diluted to 1:25 (OD600 = 0.1). Treatment with (D) ceftriaxone (25 µg/ml) and (E) cefotaxime (50 µg/ml) was added to overnight cultures of Klebsiella pneumoniae strains diluted to 1:25 (OD600 = 0.1). After incubation with antibiotics for 30 min, SYBR Green I/PI staining was performed and distinguished their respective susceptibility categories. All susceptibility results were in concordance with results from the Kirby–Bauer disk diffusion test (Student’s t-test, *p < 0.05, **p < 0.05, ***p < 0.0005). Data represent the means + SEMs.

Click on the image to see a larger version.